IPALT

iPALT
Clinical data
Other namesALiPT; ASR-3003; ASR3003; N-Isopropyl-N-allyltryptamine; N-Allyl-N-isopropyltryptamine
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
PubChem CID
Chemical and physical data
FormulaC16H22N2
Molar mass242.366 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=CC=CC=C21)CC=C
  • InChI=1S/C16H22N2/c1-4-10-18(13(2)3)11-9-14-12-17-16-8-6-5-7-15(14)16/h4-8,12-13,17H,1,9-11H2,2-3H3
  • Key:DYIILRIYTXJTNJ-UHFFFAOYSA-N

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake.[1] The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001).[1] The chemical synthesis of iPALT has been described.[1] Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002).[1] 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use.[2][3][4][5] iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]

See also

References

  1. ^ a b c d e f g h US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc. 
  2. ^ "Delving into the Latest Updates on Tryptamine(ASRI) with Synapse". Synapse. 16 April 2025. Retrieved 19 April 2025.
  3. ^ Goldstein L (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 19 April 2025.
  4. ^ Busby M (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 19 April 2025.
  5. ^ Busby M (30 March 2025). "What Happens When You Inherit 500 Psychedelic Compounds?". DoubleBlind Mag. Retrieved 19 April 2025.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.